Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Deciphera Pharmaceuticals Stock Quote

Deciphera Pharmaceuticals (NASDAQ: DCPH)

$14.67
(3.1%)
$0.44
Price as of April 19, 2024, 4:00 p.m. ET

Deciphera Pharmaceuticals Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
DCPH 0.00% -37.44% -8.94% -19%
S&P +20.62% +72.50% +11.51% +98%

Deciphera Pharmaceuticals Company Info

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.